WinstonWınston
QHSLab logo

QHSLab

USAQ
38
Medical - Devices · Healthcare
Price
$0.32
+0.00 (+0.00%)
Market Cap
$3.9M
Winston Score
38
Winston is serious
Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+146.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.9M (2021) → 19.3M (2025)

QHSLab, Inc. is a small healthcare company that sells tools and programs to help doctors monitor and improve their patients' health. Its main products are digital health assessments and wellness solutions sold directly to medical practices and healthcare providers across the United States. The company focuses on giving doctors easy-to-use software and testing kits so they can track things like nutrition, sleep, and overall wellness for their patients.

QHSLab makes money by selling its products and services to doctors and clinics, likely through a mix of product sales and recurring service fees. It operates entirely in the U.S. and is a very small company, with a market cap under $10 million. Its 66% gross margin suggests decent pricing power on its products, but its razor-thin operating margin means it has little room for error. The biggest risk the company faces is scaling up sales fast enough to survive as a tiny player competing against much larger digital health companies with bigger budgets and brand recognition.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+12.9% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

+2.8% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$484,873/ year

Rising (+65% vs prior year)

18.0% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

48.1%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~5 months

$362,088 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

QHSLab is putting 18% of revenue into R&D and that number is rising.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
64.6%
Premium pricing power — 64.6% gross margin
Operating Margin
-10.5%
Losing money on operations — -10.5%
ROCE
-5.0%
Weak — -5.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+21.2%
Fast-growing sales (21.2% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
6%
Weak — only 6% of profit becomes cash
FCF Margin
1.0%
Thin free cash flow (1.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
0.42x
Dangerous — barely covers interest (0.4x)

Interest coverage below 1. Their profits don't cover the interest bill.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
7.9x
Attractive valuation — P/E 7.9

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
+7.0
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (7.9 → 0.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial